Loading
Loading
The research-peptide market has a trust problem - opaque sourcing, unverifiable lab claims, and vendors who vanish after payment. We built Caesar Biomedical to be the opposite: a transparent, science-first company for researchers and clinicians who actually read a Certificate of Analysis. Peptide medicine is not new. It began with insulin in 1921. We treat it with the seriousness that lineage deserves.
Our compounds are synthesized at pharmaceutical-grade facilities in South Korea - one of the most advanced peptide-manufacturing industries in the world.
Every lot is tested at accredited third-party laboratories in Dubai and the United Kingdom - independent of the manufacturer, with HPLC, mass-spec, and endotoxin panels.
Each order ships with a per-lot Certificate of Analysis. The lot number on your vial maps back to its synthesis facility and its testing laboratory.
Every compound we ship descends from the same chain of discoveries that began with insulin. Peptide medicine is not new - it is one of the oldest, most-studied, and most successful chapters in modern pharmaceutical science.
Frederick Banting and Charles Best purify insulin at the University of Toronto. A 14-year-old patient on the verge of death is treated in January 1922. The Nobel Prize follows in 1923. The first peptide medicine.
Frederick Sanger sequences insulin - the first protein ever sequenced. The work that proved peptides have a defined chemical identity and earns him the first of two Nobel Prizes.
Oxytocin is chemically synthesized by Vincent du Vigneaud and brought to market. Solid-phase peptide synthesis (Merrifield, also Nobel) makes industrial peptide manufacturing possible.
Researchers identify glucagon-like peptide-1 in the gut. It signals satiety and modulates insulin release. The molecular handle for the next forty years of metabolic medicine.
The pentadecapeptide fragment of a protective protein in human gastric juice is isolated and given the BPC designation. Preclinical tissue-repair research follows.
Semaglutide (Ozempic) reaches patients. Significant weight and glycemic effects. The peptide class becomes one of the most-prescribed medicines on Earth.
Retatrutide reports the largest weight-loss effects ever observed in a clinical trial of its class. Triple-receptor pharmacology (GIP + GLP-1 + glucagon) becomes the new frontier.
Pharmaceutical-grade synthesis. Per-lot HPLC and mass-spec verification. Certificates of analysis with every order. The compounds insulin made possible, shipped with the same level of seriousness.
Our catalog was not selected for breadth. It was selected because each compound is the most-studied research peptide in its mechanistic family - the molecule the literature has actually converged on.
01
Retatrutide engages three incretin receptors simultaneously (GIP, GLP-1, glucagon). Published Phase-2 research has reported the largest fat-mass reductions yet observed in this class - with a body-composition profile that points toward better lean-mass retention than earlier GLP-1 monotherapies.
Retatrutide
02
BPC-157 (a 15-amino-acid fragment of a gastric-juice protective protein) and TB-500 (a fragment of Thymosin Beta-4) are two of the most-studied research peptides in the tissue-repair literature. Preclinical work has examined tendon, ligament, gut barrier, and angiogenic signaling.
BPC-157 · TB-500
03
GHK-Cu, MOTS-c, and NAD+ all sit inside the modern longevity research conversation. GHK-Cu modulates dozens of gene-expression pathways; MOTS-c is a mitochondrially-derived metabolic regulator; NAD+ is the coenzyme central to sirtuin signaling and DNA repair.
GHK-Cu · MOTS-c · NAD+
04
PT-141 (bremelanotide) is an FDA-approved peptide therapeutic (marketed as Vyleesi since 2019) that targets the MC3R / MC4R melanocortin receptors. A worked example of how a research peptide moves through Phase-3 trials and into the regulated pharmaceutical channel.
PT-141
We sell molecules. Not protocols, not dosing schedules, not therapeutic claims.
Caesar Biomedical is a research-peptide vendor. The compounds we ship are sold for laboratory research use only. Mechanism descriptions on this page reference published preclinical and clinical literature - not claims about product outcomes. Any therapeutic application is your decision, made under your own clinical or research framework.
Where the research-peptide market is opaque, we are explicit. Documentation, verification, and chain-of-custody are how we earn the right to ship a compound that descends from insulin.
Caesar Biomedical
RecommendedGeneric research vendor
Pharmacy compounder
Grey-market supplier
For laboratory research use only. Comparison reflects typical market practice as of 2026.
Join the research letter for monthly briefings on peptide science, lab data updates, and the kind of writing your inbox actually deserves.
The research letter
One email per month. Citations included. Zero filler.